NovoCure Stock Forecast, Price & News

-9.99 (-6.09 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.43 million shs
Average Volume682,048 shs
Market Capitalization$15.93 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NovoCure logo

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.21 out of 5 stars

Medical Sector

319th out of 2,220 stocks

Surgical & Medical Instruments Industry

36th out of 185 stocks

Analyst Opinion: 2.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure
or view top-rated stocks.

What stocks does MarketBeat like better than NovoCure?

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NovoCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for NovoCure

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its earnings results on Thursday, July, 29th. The medical equipment provider reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.16. NovoCure had a negative trailing twelve-month return on equity of 1.19% and a negative net margin of 0.84%.
View NovoCure's earnings history

How has NovoCure's stock been impacted by COVID-19 (Coronavirus)?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 128.6% and is now trading at $154.01.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NVCR?

8 analysts have issued 12 month price objectives for NovoCure's stock. Their forecasts range from $142.00 to $250.00. On average, they anticipate NovoCure's stock price to reach $186.14 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price.
View analysts' price targets for NovoCure
or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?

NovoCure's management team includes the following people:
  • Mr. William F. Doyle, Exec. Chairman (Age 59, Pay $1.83M)
  • Mr. Asaf Danziger, Pres, CEO & Director (Age 55, Pay $2.01M)
  • Ms. Ashley Cordova, CFO & VP of Investor Relations (Age 42, Pay $995.2k)
  • Mr. Wilhelmus C. M. Groenhuysen, Chief Operating Officer (Age 63, Pay $1.44M)
  • Mr. Todd C. Longsworth, Gen. Counsel (Age 46, Pay $1.15M)
  • Mr. Pritesh Shah, Chief Commercial Officer (Age 43, Pay $946.17k)
  • Prof. Yoram Palti, Founder & CTO (Age 83)
  • Dr. Ely Benaim, Chief Medical Officer (Age 60)
  • Mr. Uri Weinberg M.D., Ph.D., Chief Science Officer
  • Mr. Frank Leonard, Chief Devel. Officer

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Asaf Danziger has an approval rating of 90% among NovoCure's employees.

Who are some of NovoCure's key competitors?

What other stocks do shareholders of NovoCure own?

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.05%), Scout Investments Inc. (0.05%), Advisors Asset Management Inc. (0.03%), Taylor Frigon Capital Management LLC (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Hodges Capital Management Inc. (0.02%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure

Which major investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Taylor Frigon Capital Management LLC, Hodges Capital Management Inc., Alliancebernstein L.P., Exchange Traded Concepts LLC, Advisors Asset Management Inc., Fort Point Capital Partners LLC, and Teamwork Financial Advisors LLC. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure
or view top insider-selling stocks.

Which major investors are buying NovoCure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including Highland Capital Management LLC, Derbend Asset Management, Zurcher Kantonalbank Zurich Cantonalbank , Oregon Public Employees Retirement Fund, Emerald Advisers LLC, Patriot Financial Group Insurance Agency LLC, Stratos Wealth Partners LTD., and Fulton Bank N.A..
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $154.01.

How much money does NovoCure make?

NovoCure has a market capitalization of $15.93 billion and generates $494.37 million in revenue each year. The medical equipment provider earns $19.81 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,023 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is

Where are NovoCure's headquarters?

NovoCure is headquartered at NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.